Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Roboz

Showing results (241-250 of 276) with videos related to

Pageof 28
Sort By:
Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Blood|December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenibEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Science Translational Medicine|February 21, 2014
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaMarco L Davila, Isabelle Riviere, Xiuyan Wang, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Cancer Cell|November 1, 2019
Paradigms for Precision Medicine in Epichaperome Cancer TherapyNagavarakishore Pillarsetty, Komal Jhaveri, Tony Taldone, et al.
The Lancet. Haematology|December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 studyGuillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
NPJ Precision Oncology|May 27, 2021
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemiaMayumi Sugita, David C Wilkes, Rohan Bareja, et al.
Nature Medicine|June 21, 2016
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemiaSheng Li, Francine E Garrett-Bakelman, Stephen S Chung, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Pageof 28

Showing results (241-250 of 276) with videos related to

Sort By:
Pageof 28
Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Blood|December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenibEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Science Translational Medicine|February 21, 2014
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaMarco L Davila, Isabelle Riviere, Xiuyan Wang, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Cancer Cell|November 1, 2019
Paradigms for Precision Medicine in Epichaperome Cancer TherapyNagavarakishore Pillarsetty, Komal Jhaveri, Tony Taldone, et al.
The Lancet. Haematology|December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 studyGuillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
NPJ Precision Oncology|May 27, 2021
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemiaMayumi Sugita, David C Wilkes, Rohan Bareja, et al.
Nature Medicine|June 21, 2016
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemiaSheng Li, Francine E Garrett-Bakelman, Stephen S Chung, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Pageof 28